Schering AG agrees to license Refludan
The Federal Trade Commission is accepting comments until Sept. 12 on a proposal by Aventis to divest the direct thrombin inhibitor Refludan (lepirudin) to Schering AG. Aventis was ordered to divest Refludan after failing to complete a divestment of the pending Revasc (desirudin), as required under the FTC consent agreement allowing the merger of Hoechst and Rhone-Poulenc (1"The Pink Sheet" Sept. 4, 2000, p. 17)
You may also be interested in...
Aventis' Refludan is available for licensing through the New York City investment banking company Ferghana Partners as a result of an Aug. 25 Federal Trade Commission order.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials